HSE - PCRS

Application Details

HSE Application ID

HSE100125

HTA Number

26032

HTA Link

https://www.ncpe.ie/mavorixafor-xolremdi-hta-id-26032/

Drug

mavorixafor

Brand

Xolremdi®

Applicant

Norgine B.V.

Indication Applied For

Indicated in patients 12 years of age and older for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes.

Application Date

20/07/2026

Marketing Authorisation Date

27/04/2026

Application Status

Rapid Review Completed: On the basis of current evidence, the NCPE recommends that the product not be considered for reimbursement.

30/07/2026

Rapid Review Completed

30/07/2026

Pricing and Reimbursement Application Complete

20/07/2026

Rapid Review Commissioned

03/07/2026

New Search